In managing type 2 diabetes, what is the first-line pharmacologic agent and its primary mechanism?

Study for the Medical FIDSAP v2 Test. Sharpen your skills with flashcards and multiple-choice questions, complete with hints and explanations. Prepare effectively for your upcoming test!

Multiple Choice

In managing type 2 diabetes, what is the first-line pharmacologic agent and its primary mechanism?

Metformin is the first-line pharmacologic choice for most adults with type 2 diabetes because it effectively lowers glucose with a favorable safety profile. Its primary action is to reduce hepatic glucose production while also improving insulin sensitivity in tissues, especially muscles. It works mainly by activating AMPK in the liver, which suppresses hepatic gluconeogenesis, leading to lower fasting glucose and better overall glycemic control. The drug tends to cause little or no hypoglycemia when used alone and is often associated with weight neutrality or modest weight loss, plus cost and cardiovascular data that support its use. Other drug classes act through different mechanisms—some increase insulin secretion, some enhance incretin effects, and some require injections—and they generally carry higher risks of hypoglycemia or weight gain or are used later in therapy. Metformin’s combination of efficacy, safety, and cost makes it the preferred starting pharmacologic agent. Note that metformin is not used in patients with significant renal impairment and should be reconsidered or dose-adjusted if there are concerns about kidney function or risk of lactic acidosis.

Metformin is the first-line pharmacologic choice for most adults with type 2 diabetes because it effectively lowers glucose with a favorable safety profile. Its primary action is to reduce hepatic glucose production while also improving insulin sensitivity in tissues, especially muscles. It works mainly by activating AMPK in the liver, which suppresses hepatic gluconeogenesis, leading to lower fasting glucose and better overall glycemic control. The drug tends to cause little or no hypoglycemia when used alone and is often associated with weight neutrality or modest weight loss, plus cost and cardiovascular data that support its use.

Other drug classes act through different mechanisms—some increase insulin secretion, some enhance incretin effects, and some require injections—and they generally carry higher risks of hypoglycemia or weight gain or are used later in therapy. Metformin’s combination of efficacy, safety, and cost makes it the preferred starting pharmacologic agent. Note that metformin is not used in patients with significant renal impairment and should be reconsidered or dose-adjusted if there are concerns about kidney function or risk of lactic acidosis.

More practice questions